annual shareholders equity:
$1.42B+$924.20M(+184.56%)Summary
- As of today (May 29, 2025), RNA annual stockholders equity is $1.42 billion, with the most recent change of +$924.20 million (+184.56%) on December 31, 2024.
- During the last 3 years, RNA annual shareholders equity has risen by +$1.04 billion (+273.58%).
- RNA annual shareholders equity is now at all-time high.
Performance
RNA Shareholders equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly shareholders equity:
$1.33B-$96.24M(-6.75%)Summary
- As of today (May 29, 2025), RNA quarterly stockholders equity is $1.33 billion, with the most recent change of -$96.24 million (-6.75%) on March 31, 2025.
- Over the past year, RNA quarterly shareholders equity has increased by +$497.82 million (+59.91%).
- RNA quarterly shareholders equity is now -11.62% below its all-time high of $1.50 billion, reached on September 30, 2024.
Performance
RNA quarterly shareholders equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Shareholders equity Formula
Shareholders Equity = Total Assets − Total Liabilities
RNA Shareholders equity Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +184.6% | +59.9% |
| 3 y3 years | +273.6% | +253.7% |
| 5 y5 years | +2280.3% | +1913.2% |
RNA Shareholders equity Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +273.6% | -11.6% | +254.9% |
| 5 y | 5-year | at high | +2280.3% | -11.6% | +1913.2% |
| alltime | all time | at high | +2280.3% | -11.6% | +2133.0% |
RNA Shareholders equity History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $1.33B(-6.8%) |
| Dec 2024 | $1.42B(+184.6%) | $1.42B(-5.2%) |
| Sep 2024 | - | $1.50B(+23.1%) |
| Jun 2024 | - | $1.22B(+47.0%) |
| Mar 2024 | - | $830.90M(+65.9%) |
| Dec 2023 | $500.76M(-13.4%) | $500.76M(-3.2%) |
| Sep 2023 | - | $517.47M(-7.5%) |
| Jun 2023 | - | $559.18M(+0.0%) |
| Mar 2023 | - | $558.91M(-3.3%) |
| Dec 2022 | $578.08M | $578.08M(+53.3%) |
| Sep 2022 | - | $376.98M(+0.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $374.35M(-0.4%) |
| Mar 2022 | - | $375.71M(-1.5%) |
| Dec 2021 | $381.43M(+24.6%) | $381.43M(-3.4%) |
| Sep 2021 | - | $394.88M(+49.3%) |
| Jun 2021 | - | $264.48M(-7.6%) |
| Mar 2021 | - | $286.12M(-6.6%) |
| Dec 2020 | $306.22M(-568.5%) | $306.22M(-4.4%) |
| Sep 2020 | - | $320.16M(-3.1%) |
| Jun 2020 | - | $330.30M(+400.4%) |
| Mar 2020 | - | $66.00M(-201.0%) |
| Dec 2019 | -$65.36M(+58.9%) | -$65.36M |
| Dec 2018 | -$41.13M | - |
FAQ
- What is Avidity Biosciences annual stockholders equity?
- What is the all time high annual shareholders equity for Avidity Biosciences?
- What is Avidity Biosciences annual shareholders equity year-on-year change?
- What is Avidity Biosciences quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Avidity Biosciences?
- What is Avidity Biosciences quarterly shareholders equity year-on-year change?
What is Avidity Biosciences annual stockholders equity?
The current annual shareholders equity of RNA is $1.42B
What is the all time high annual shareholders equity for Avidity Biosciences?
Avidity Biosciences all-time high annual stockholders equity is $1.42B
What is Avidity Biosciences annual shareholders equity year-on-year change?
Over the past year, RNA annual stockholders equity has changed by +$924.20M (+184.56%)
What is Avidity Biosciences quarterly stockholders equity?
The current quarterly shareholders equity of RNA is $1.33B
What is the all time high quarterly shareholders equity for Avidity Biosciences?
Avidity Biosciences all-time high quarterly stockholders equity is $1.50B
What is Avidity Biosciences quarterly shareholders equity year-on-year change?
Over the past year, RNA quarterly stockholders equity has changed by +$497.82M (+59.91%)